EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma.
Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, Zou Z, Li P, Guo Q, Ma L, He C, Huang S. · 2021
Read EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. by Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, Zou Z, Li P, Guo Q, Ma L, He C, Huang S. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7794382.txt.
Introduction
Fang and co-authors trace how the protein YTHDF2 drives aggressive growth in glioblastoma. Glioblastoma is the most common malignant brain tumor in adults. Its molecular drivers are still poorly mapped. Little was known about YTHDF2 in this disease.
High YTHDF2 levels matched poor patient survival. The growth factor receptor EGFR drives that rise. A signaling chain through SRC and ERK steadies the YTHDF2 protein. YTHDF2 then speeds decay of two gene messages, LXRA and HIVEP2. That decay disturbs cholesterol control in tumor cells. It also fuels cell growth, invasion, and tumor formation. Blocking this chain is proposed as a treatment angle.
Catalog record
| CREATOR | Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, Zou Z, Li P, Guo Q, Ma L, He C, Huang S. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 81 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma By Runping Fang, Xin Chen, Sicong Zhang, Hui Shi, Youqiong Ye, Hailing Shi, Zhongyu Zou, Peng Li, Qing Guo, Li Ma, Chuan He, Suyun Huang Published in: Nature Communications DOI: 10.1038/s41467-020-20379-7 ABSTRACT Glioblastoma (GBM) is the most common type of adult malignant brain tumor, but its molecular mechanisms are not well understood. In addition, the knowledge of the disease-associated expression and function of YTHDF2 remains very limited. Here, we show that YTHDF2 overexpression clinically correlates with poor glioma patient prognosis. EGFR that is constitutively activated in the majority of GBM causes YTHDF2 overexpression through the EGFR/SRC/ERK pathway. EGFR/SRC/ERK signaling phosphorylates YTHDF2 serine39 and threonine381, thereby stabilizes YTHDF2 protein. YTHDF2 is required for GBM cell proliferation, invasion, and tumorigenesis. YTHDF2 facilitates m6A-dependent mRNA decay of LXRA and HIVEP2, which impacts the glioma patient survival. YTHDF2 promotes tumorigenesis of GBM cells, largely through the downregulation of LXRα and HIVEP2. Furthermore, YTHDF2 inhibits LXRα-dependent cholesterol homeostasis in GBM cells. Together, our findings extend the landscape of EGFR downstream circuit, uncover the function of YTHDF2 in GBM tumorigenesis, and highlight an essential role of RNA m6A methylation in cholesterol homeostasis. INTRODUCTION Glioblastomas (GBM; World Health Organization grade IV glioma) are a devastating type of brain tumor, with a median survival of 14 months, regardless of treatment1. The tumor cells that invade adjacent brain tissue and contribute to the intracranial dissemination of GBM, represent a major clinical problem. The proliferation and invasion capacities of glioblastomas are a consequence of the interplay of multiple layers of altered molecular regulations. The most prevailing genetic alterations are the amplification and mutation of EGFR that occur in more than 50% of GBMs1. EGFRvIII, lacking part of the extracellular region, is a frequent activating oncogenic mutant2. EGFR activation by amplification, mutation, and ligand-binding in an autocrine or paracrine manner can accelerate GBM formation and is associated with poor prognosis. EGFR signaling has been reported to confer global effects on the modulation of multiple pathways in GBM. However, the effects of EGFR activation on mRNA modification are less known. N6-methyladenosine (m6A) modification is the most prevalent internal modification existing on eukaryotic mRNA3. We and others have recently shown that aberrant mRNA m6A modifications actively assist the tumorigenicity of glioblastoma stem cells4,5. m6A-modified mRNA can be preferentially recognized by the members of the human YTH domain family, the ‘reader’ proteins, such as YTHDF26,7. Among the mammalian YTH family proteins, YTHDF2 has been shown to destabilize m6A-marked transcripts through deadenylation by the CCR4–NOT complex, or through endoribonucleolytic cleavage, with the help of HRSP12-RNase P/MRP7–9. Depletion of Ythdf2 leads to mouse embryonic lethality due to the failure of neural stem/progenitor cell proliferation and differentiation10,11. Despite the important roles of YTHDF2 in brain development and function, it is unknown whether this reader is presented in GBM and affects GBM propagation. Dysregulated cholesterol metabolism by cancer epigenetic regulators is another hallmark of GBM12. Cholesterol metabolism is under the transcriptional control of sterol regulatory element-binding proteins (SREBPs) and liver X receptors (LXRs). SREBPs promote cholesterol synthesis and enhance the uptake of extracellular cholesterol13. EGFR mutation in GBM has been shown to increase the PI3K-dependent activation of SREBP114. LXRs induce cholesterol efflux by regulating the expression of apolipoprotein E (ApoE), a major apolipoprotein in the CNS that mediates the transport of cholesterol, and its transporters ABCA1 and ABCG1. LXRs also suppress cholesterol uptake by enhancing the degradation of LDLR15,16. Although LXR agonists have been reported to cause GBM regression12,14, the regulatory mechanisms for LXRs expression in GBM remain unclear. In the current study, we investigate m6A YTH readers in GBM, and observe a correlation between increased expression of YTHDF2 and decreased survival of glioma patients. We identify a regulatory role of EGFR activation in YTHDF2 overexpression and elucidate the underlying mechanisms in GBM cells. We also determine the biological consequences of EGFR-mediated induction of YTHDF2 on the tumorigenicity of GBM cells. Mechanistically, we uncover that YTHDF2 accelerates m6A-dependent LXRA mRNA degradation, thereby promoting cholesterol dysregulation in GBM cells. YTHDF2 also promotes the mRNA degradation of HIVEP2 that is critical to GBM tumorigenesis. RESULTS YTHDF2 expression is increased in GBMs and correlates with poor prognosis After showing the vital role of m6A erasers in GBM development5, we are interested in the roles of m6A readers, especially those of YTH domain family proteins, which impact diverse biological processes, in glioma tumorigenesis. We first queried The Cancer Genome Atlas (TCGA)17,18, REMBRANDT19, French20, Kawaguchi21, and Paugh22 datasets, and found the expression of YTHDF2, but not YTHDF1, YTHDF3, YTHDC1, or YTHDC2 correlates with poor overall survival of glioma patients in all of the datasets (Fig. 1a–c, Supplementary Fig. 1a-b). Moreover, the expression of YTHDF2 in GBMs increased as compared with normal brains in TCGA and REMBRANDT datasets (Fig. 1d).Fig. 1YTHDF2 is highly expressed in glioblastoma and predicts poor prognosis of glioma patients.a Kaplan–Meier overall survival plot showing survival rates for lower-grade glioma and GBM patients having YTHDF2 low expression (blue), and high expression (red) in the TCGA PanCancer Atlas dataset (http://www.cbioportal.org) (two-sided log-rank test). b Kaplan–Meier overall survival plot showing survival rates for glioma patients having YTHDF2 low expression (blue), and high expression (red) in REMBRANDT dataset (two-sided log-rank test). c Kaplan–Meier overall survival plot showing survival rates for glioma patients having YTHDF2 low expression (blue), and high expression (red) in French dataset (two-sided log-rank test). d Profile of YTHDF2 mRNA expression in normal, GBM, or grade I–III glioma patients in TCGA and REMBRANDT datasets. e Analysis of YTHDF2 protein expression in 2 TMAs with 14 normal cores, 10 grade I astrocytomas cores, 47 grade II astrocytomas cores, 33 grade III astrocytomas cores, and 34 GBM cores; and in 36 GBM tissues, using immunohistochemical analysis. Scale bar = 100 μm. Representative image of two independent experiments. f Summary of YTHDF2 protein expression profile in (e). IHC staining score 0–1, low; 2–8, medium; 9–12, high (Kruskal–Wallis test and the post hoc Dunn’s multiple comparisons test). g Western blotting of YTHDF2 in glioma cells (Hs683, SW1783), GBM cells (T98G, U87 MG, U251 MG, LN229), and GSCs (GSC11, GSC17, GSC20, GSC23, GSC7-2, GSC6-27). Representative blot of two independent experiments. Source data are provided as a Source data file. We then examined the protein levels of YTHDF2 in human glioma specimens. YTHDF2 shows higher protein expression in tumor relative to adjacent non-tumor tissue (Supplementary Fig. 1c). Notably, the expression of YTHDF2 protein is significantly increased in GBM and correlates with tumor grade (Fig. 1e, f). In cultured glioma tumor cell lines and normal human astrocytes, YTHDF2 protein is highly expressed in GBM cells, especially in GBM-derived stem cells (GSCs), as compared with lower-grade glioma cells (Hs683 and SW1783) and normal human astrocytes (Fig. 1g and Supplementary Fig. 1d). Moreover, YTHDF2 protein expression is reduced upon induced differentiation of GSCs (Supplementary Fig. 1e). Collectively, these results suggest that YTHDF2 might be involved in the malignancy of glioma. YTHDF2 regulates GBM cell proliferation, invasion, and tumorigenesis To examine the role of YTHDF2 in GBM tumorigenesis, we used two distinct short hairpin RNAs targeting the 3′UTR (shYTHDF2#1) or the CDS (shYTHDF2#2) of YTHDF2 mRNA to ablate YTHDF2 expression in GSC11 and GSC7-2 cells (Supplementary Fig. 2a). Loss of YTHDF2 in